Cargando…

Correction: Delphinidin-3-Glucoside Protects against Oxidized Low-Density Lipoprotein-Induced Mitochondrial Dysfunction in Vascular Endothelial Cells via the Sodium-Dependent Glucose Transporter SGLT1

Detalles Bibliográficos
Autores principales:	Jin, Xin, Yi, Long, Chen, Ming-liang, Chen, Chun-ye, Chang, Hui, Zhang, Ting, Wang, Li, Zhu, Jun-dong, Zhang, Qian-yong, Mi, Man-tian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3908741/ http://dx.doi.org/10.1371/annotation/774b483b-cba3-46ce-a922-09d7f05487b0

Ejemplares similares

Delphinidin-3-Glucoside Protects against Oxidized Low-Density Lipoprotein-Induced Mitochondrial Dysfunction in Vascular Endothelial Cells via the Sodium-Dependent Glucose Transporter SGLT1
por: Jin, Xin, et al.
Publicado: (2013)

Virtual Prediction of the Delphinidin-3-O-glucoside and Peonidin-3-O-glucoside as Anti-inflammatory of TNF-α Signaling
por: Sari, Dewi Ratih Tirto, et al.
Publicado: (2019)

Delphinidin-3-glucoside suppresses breast carcinogenesis by inactivating the Akt/HOTAIR signaling pathway
por: Yang, Xiaohong, et al.
Publicado: (2016)

Sodium glucose transporter 2 (SGLT2) inhibition and ketogenesis
por: Kalra, Sanjay, et al.
Publicado: (2015)

Anthocyanins, delphinidin-3-O-glucoside and cyanidin-3-O-glucoside, inhibit immune checkpoints in human colorectal cancer cells in vitro and in silico
por: Mazewski, Candice, et al.
Publicado: (2019)

Delphinidin-3-O-glucoside, an active compound of Hibiscus sabdariffa calyces, inhibits oxidative stress and inflammation in rabbits with atherosclerosis
por: Sun, Bo, et al.
Publicado: (2022)

Effect of Soybean Protein Isolate-7s on Delphinidin-3-O-Glucoside from Purple Corn Stability and Their Interactional Characterization
por: Chen, Dongxia, et al.
Publicado: (2022)

Plant Food Delphinidin-3-Glucoside Significantly Inhibits Platelet Activation and Thrombosis: Novel Protective Roles against Cardiovascular Diseases
por: Yang, Yan, et al.
Publicado: (2012)

Chemical Structures of 4-Oxo-Flavonoids in Relation to Inhibition of Oxidized Low-Density Lipoprotein (LDL)-Induced Vascular Endothelial Dysfunction
por: Yi, Long, et al.
Publicado: (2011)

The Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitor Empagliflozin Reverses Hyperglycemia-Induced Monocyte and Endothelial Dysfunction Primarily through Glucose Transport-Independent but Redox-Dependent Mechanisms
por: Semo, Dilvin, et al.
Publicado: (2023)

Anti-Adipogenic Effects of Delphinidin-3-O-β-Glucoside in 3T3-L1 Preadipocytes and Primary White Adipocytes
por: Park, Miey, et al.
Publicado: (2019)

Apical Localization of Sodium-Dependent Glucose Transporter SGLT1 is Maintained by Cholesterol and Microtubules
por: Suzuki, Takeshi, et al.
Publicado: (2006)

The Role of Sodium-Dependent Glucose Transporter 1 and Glucose Transporter 2 in the Absorption of Cyanidin-3-O-β-Glucoside in Caco-2 Cells
por: Zou, Tang-Bin, et al.
Publicado: (2014)

Delphinidin Inhibits Tumor Growth by Acting on VEGF Signalling in Endothelial Cells
por: Keravis, Thérèse, et al.
Publicado: (2015)

Real‐time imaging of sodium glucose transporter (SGLT1) trafficking and activity in single cells
por: Ghezzi, Chiara, et al.
Publicado: (2017)

Fournier's Gangrene and Sodium-glucose Co-transporter 2(SGLT2) Inhibitors: Our Experience
por: Dass, Ashwitha S., et al.
Publicado: (2019)

Sodium‐Glucose Co‐Transporter 2 (SGLT2) Inhibitor Dapagliflozin Stabilizes Diabetes‐Induced Atherosclerotic Plaque Instability
por: Chen, Yung‐Chih, et al.
Publicado: (2021)

Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agents
por: Vivian, Eva M
Publicado: (2014)

Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical Pharmacology
por: Kalra, Sanjay
Publicado: (2014)

The metabolic model of heart failure: the role of sodium glucose co-transporter-2 (SGLT-2) inhibition
por: Saad, Muhammad, et al.
Publicado: (2018)

Exploring Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors for Organ Protection in COVID-19
por: Fernandez-Fernandez, Beatriz, et al.
Publicado: (2020)

Out-of-Pocket Costs for SGLT-2 (Sodium-Glucose Transport Protein-2) Inhibitors in the United States
por: Aggarwal, Rahul, et al.
Publicado: (2021)

Safety profile of sodium glucose co-transporter 2 (SGLT2) inhibitors: A brief summary
por: Mascolo, Annamaria, et al.
Publicado: (2022)

Safety of sodium-glucose transporter 2 (SGLT-2) inhibitors in patients with type 2 diabetes: a meta-analysis of cohort studies
por: Li, Chun Xing, et al.
Publicado: (2023)

GI inflammation Increases Sodium-Glucose Cotransporter Sglt1
por: Park, Jiyoung, et al.
Publicado: (2019)

Conformational transitions of the sodium-dependent sugar transporter, vSGLT
por: Paz, Aviv, et al.
Publicado: (2018)

Osmotic Water Transport with Glucose in GLUT2 and SGLT
por: Naftalin, Richard J.
Publicado: (2008)

High-density lipoproteins attenuate high glucose-impaired endothelial cell signaling and functions: potential implications for improved vascular repair in diabetes
por: Chen, Xing, et al.
Publicado: (2017)

Sodium-Glucose Transporter-2 (SGLT2; SLC5A2) Enhances Cellular Uptake of Aminoglycosides
por: Jiang, Meiyan, et al.
Publicado: (2014)

Erratum to: Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical Pharmacology
por: Kalra, Sanjay
Publicado: (2015)

Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor: Comparing Trial Data and Real-World Use
por: McGovern, Andrew, et al.
Publicado: (2017)

Protective Effect of Irisin on Atherosclerosis via Suppressing Oxidized Low Density Lipoprotein Induced Vascular Inflammation and Endothelial Dysfunction
por: Zhang, Yuzhu, et al.
Publicado: (2016)

Cytotoxic effects of delphinidin in human osteosarcoma cells()
por: Lee, Dong-Yeong, et al.
Publicado: (2018)

Anticipatory Role of High Density Lipoprotein and Endothelial Dysfunction: An Overview
por: Eren, Esin, et al.
Publicado: (2014)

Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes
por: Neumiller, Joshua J
Publicado: (2014)

Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis
por: Donnan, Jennifer R, et al.
Publicado: (2019)

Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors: Comparing Trial and Real World Use (Study Protocol)
por: McGovern, Andrew, et al.
Publicado: (2017)

Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: A State-of-the-Art Review
por: Lopaschuk, Gary D., et al.
Publicado: (2020)

Sodium/glucose Co-Transporter 2 Inhibitor, Empagliflozin, Alleviated Transient Expression of SGLT2 after Myocardial Infarction
por: Lee, Soo Yong, et al.
Publicado: (2020)

Overview of Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitors for the Treatment of Non-diabetic Heart Failure Patients
por: Balan, Irina, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_udb8g73op8mb81l9oqi7htm44m